Drug Profile

GSK 3884464

Alternative Names: GSK-3884464

Latest Information Update: 28 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GlaxoSmithKline
Developer GSK
Class Heart failure therapies
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Heart failure

Most Recent Events

28 Oct 2024 No recent reports of development identified for phase-I development in Heart-failure(In volunteers) in United Kingdom (PO)
16 Aug 2023 GlaxoSmithKline terminates a first-in-human phase I trial for Heart failure (In volunteers) in United Kingdom (PO) to allow for additional assessments from supplementary non-clinical activities (NCT05044325)
20 Sep 2021 Phase-I clinical trials in Heart failure (In volunteers) in United Kingdom (PO) (NCT05044325)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com